We are a fully independent, biomedical research institution with the vision, drive and infrastructure to accelerate new treatment ideas from the laboratory through clinical trials and on to patients. Our onsite biologic manufacturing labs accelerate this process, as do our collaborative research efforts.

Our Musculoskeletal Tumor Program pursues joint initiatives with colleagues on campus as well as with researchers nationwide. Complementing these efforts, we have the longest-standing cancer survivorship program in the country.

In a concerted effort to develop viable treatments that significantly improve cancer survival, musculoskeletal investigators collaborate across disciplines to develop the most promising therapies. 

Below is a sampling of some of our current research initiatives:

Halting Cancer from Multiplying and Spreading  
Our researchers are developing novel therapies that block musculoskeletal cancer's ability to proliferate and spread throughout the body. A phase I and II study on Dasatinib, an investigational drug that acts to inhibit cancer growth and development, is scheduled to begin this year.

Increasing Cancer's Sensitivity to Chemotherapy
Using high-dose stem cell therapy combined with Topotecan, our researchers seek to increase the potency of chemotherapy against sarcoma and solid tumors. A pilot trial is currently under way. Already, Topotecan has shown promise with other cancers.

Attacking Cancer with the Immune System
By using engineered monoclonal antibodies, altered antibodies equipped with radio isotopes, our investigators are testing this therapy against sarcoma. These engineered antibodies have a unique quality -- they seek out only tumor cells, sparing normal cells.

To learn more about our clinical trials program, specifically those for musculoskeletal and pediatric cancers, click here.